BioSpace News Archive

Voluntis (Paris:VTX) (Euronext Paris, ticker: VTX - ISIN: FR0004183960), a digital therapeutics company, announced today the nominations of Jan Berger, MD, and Roberta Herman, MD, to its Board of Directors

At the 35th Annual National Oncology Conference, the Association of Community Cancer Centers (ACCC) recognized the UNC Department of Pharmacy and the North Carolina Cancer Hospital this past weekend as one of several forward-thinking cancer program members to create innovative strategies for the effective delivery of cancer care.

Ultimate Medical Academy career experts are leading career advancement workshops this morning for a group of 60 college women from across Florida as part of the 2018 Women’s Conference of Florida #WCofFL2018

2018 marks a decade of empowering Health Plans achieve speed to market, growth, and reduce costs.

CDRD LifeSciences BC, TRIUMF Innovations and BIOTECanada – are hosting an event today to build support and encourage action and agreement that will advance recommendations from The Government of Canada’s Health and Biosciences Economic Strategy Table Report.

On October 17, the Cannabis Act came into force, putting in place a new legal framework for cannabis. This fundamental shift to a new legal approach is an important step in reducing harms to Canadians and removing the burden and stigma of criminalization.

Falcon Computing Inc today announced the addition of Genome Analysis Toolkit (GATK) version 4.0 best practices pipelines on its accelerated genomics platform. GATK4, which is freely offered open-source to the genomics community from Broad Institute of MIT and Harvard, has extensive speed and scalability improvements without sacrificing renowned accuracy.

By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments

Sitka Biopharma is pleased to announce that Quark Venture Inc. and GF Securities, through their Global Health Sciences Fund (GHS), has invested $1.9M into Sitka – financing that will enable the company to complete critical GLP toxicology studies and GMP manufacture of clinical drug product.

Significant reported revenue from the agreement with Tasly Biopharmaceuticals